Global Erythromycin Market Size To Worth USD 20.43 Billion By 2033 | CAGR of 5.48%
Category: HealthcareGlobal Erythromycin Market Size To Worth USD 20.43 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the Global Erythromycin Market Size is Expected to Grow from USD 11.98 Billion in 2023 to USD 20.43 Billion by 2033, at a CAGR of 5.48% during the forecast period 2023-2033.
Get more details on this report -
Browse key industry insights spread across 238 pages with 110 Market data tables and figures & charts from the report on the "Global Erythromycin Market Size, Share, and COVID-19 Impact Analysis, By Product Type (Erythromycin Capsules, Erythromycin Topical, Erythromycin Oral Suspension, Erythromycin Injection, and Erythromycin Tablets), By Application (Skin Infections, Gastrointestinal Infections, Respiratory Tract Infections, Genital Infections, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2023 – 2033." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/erythromycin-market
The erythromycin market aims to develop and commercialize erythromycin medications for treating bacterial infections. Erythromycin is a natural antibiotic derived from Streptomyces erytreus, which acts against gram-positive and gram-negative bacteria. It is used to prevent and treat various body infections, including those of the respiratory tract, skin, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, Legionnaire's disease, pertussis, and syphilis. The market expansion is driven by government initiatives, such as the Social Awareness and Actions to Neutralize Pneumonia Successfully (SAANS) in India, which promotes prevention, treatment, and early identification of bacterial infections. The increasing cases of pneumonia, the leading cause of child deaths globally, accelerate the demand for erythromycin medications. The market is projected to exceed USD 20.43 billion by 2033 due to the positive features of erythromycin. However, side effects of erythromycin impede market growth.
The erythromycin tablets segment held the largest share of 42.74% in 2023 and is predicted to grow at a significant CAGR during the predicted period.
Based on the product type, the global erythromycin market is categorized as erythromycin capsules, erythromycin topical, erythromycin oral suspension, erythromycin injection, and erythromycin tablets. Among these, the erythromycin tablets segment held the largest share of 42.74% in 2023 and is predicted to grow at a significant CAGR during the predicted period. The segmental expansion is attributed to its effectiveness against various bacterial infections, patient convenience, precise dosing, taste masking, ease of administration, safety for children, and extended shelf life.
The respiratory tract infections segment accounted for the highest market share of 34.16% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the application, the global erythromycin market is categorized as skin infections, gastrointestinal infections, respiratory tract infections, genital infections, and others. Among these, the respiratory tract infections segment accounted for the highest market share of 34.16% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The rising incidence of respiratory tract diseases such pneumonia, bronchitis, and pertussis, as well as their potent antibacterial action against gram-positive bacteria, are contributing to the segment's expansion.
The hospital pharmacies segment accounted for the highest market share of 47.11% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe.
Based on the distribution channel, the global erythromycin market is categorized as retail pharmacies, hospital pharmacies, and online pharmacies. Among these, the hospital pharmacies segment accounted for the highest market share of 47.11% in 2023 and is expected to grow at a significant CAGR throughout the projected timeframe. The growth of this segment is attributed to the availability of a wide stock of antibiotics, quick access to medication, cost-effectiveness, and expert guidance from hospital pharmacists.
North America is expected to hold the greatest share of the global erythromycin market over the forecast period.
Get more details on this report -
North America is expected to hold the greatest share of the global erythromycin market over the forecast period. This is ascribed to the growing number of skin illnesses, the increase in research and development, and the growing share of the elderly population. rising healthcare costs, the Food and Drug Administration's (FDA) increasing acceptance of generic medications, and their growing manufacture and use.
Asia Pacific is predicted to hold the fastest-growing region of the global erythromycin market throughout the estimated period. Rapid industrialization, antibiotic production company saturation, an increase in clinical trials, population growth, the need for medical care, an increase in antibiotic sales, and an increase in bacterial illnesses are the outcomes of development.
Major key players in the global erythromycin market are Sanofi S.A., Alembic Pharmaceuticals Limited, Hikma Pharmaceuticals Plc., Lupin Limited, Astellas Pharma Inc., Cipla Limited, Akorn, Inc., Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Abbott Laboratories, Zydus Cadila, Eli Lilly Company, and others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Recent Development
- In April 2022, Nexus Pharmaceutical developed the Erythromycin Lactobionate for Injection (USP in 500mg/vial). The launch demonstrates Nexus's commitment to providing critical antibiotics when they are needed most. The antibiotic is the first of many upcoming products to be provided by Nexus as it continues to boost domestic medication production. It is available in cartons of five single-dose vials.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2023 to 2033. Spherical Insights has segmented the global erythromycin market based on the below-mentioned segments:
Global Erythromycin Market, By Product Type
- Erythromycin Capsules
- Erythromycin Topical
- Erythromycin Oral Suspension
- Erythromycin Injection
- Erythromycin Tablets
Global Erythromycin Market, By Application
- Skin Infections
- Gastrointestinal Infections
- Respiratory Tract Infections
- Genital Infections
- Others
Global Erythromycin Market, By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global Erythromycin Market, By Regional
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?